+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Injectable Drug Delivery Market: By Devices; By Drug Formulations; By Therapeutic Area; By Geography - Forecast 2010-2018

  • ID: 3339355
  • Report
  • 165 pages
  • IndustryARC
1 of 3
The Global Injectable Drug Delivery Devices Market has been analyzed with respect to the demand for devices from different countries across the globe. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2020. The drug injection devices market has been segmented into conventional injectors and self-injection devices broadly. Similarly the drug formulations market has been segmented into the conventional drugs and novel drugs segments. The therapeutic areas are further segmented and analyzed in this report.

While conventional devices are growing at a CAGR of 7.37%, self-injection devices are expected to grow at 16.6% during 2013 – 2018. Conventional injection devices hold around 87% market share currently but this is expected to decrease to around 83% by 2018, as the use of self-injection devices increases in the next 5 years.

The global injectable drug delivery devices market is expected to increase from around $ 11.6 bn in 2013 to around $ 17.5 bn in 2018. Self-injection devices are expected to grow at the highest growth rate of 16.1% with conventional injection devices growing at only 7.4% during the forecast period 2013 – 2018.

Analyzing the competitive landscape of the global conventional injectable devices market for 2012 IndustryARC is of the opinion that Becton Dickinson & Co. had the top position with a market share of around 27% followed by Baxter International Inc with a share of 23%. Overall these two companies along with Terumo Corporation and Schott AG together held market share of around 85%.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End user profiling
3.2.3. Patent Analysis
3.2.4. Top 5 Financials Analysis

4. Global Injectable Drug Delivery - Market Forces
4.1. Market Drivers
4.1.1. Inherent Use Case Scenario of IDD Devices With Biologics
4.1.2. Increase in Global Diabetic Population and Usage of Insulin Pens
4.1.3. Others
4.2. Market Constraints
4.2.1. Infection Risks And Government Laws
4.2.2. Others
4.3. Market Challenges
4.3.1. Higher Manufacturing Standards Needed to Avoid Product Recalls
4.3.2. Others
4.4. Attractiveness of the Industry
4.4.1. Power of Suppliers
4.4.2. Power of Customers
4.4.3. Threat of New entrants
4.4.4. Threat of Substitution
4.4.5. Degree of Competition

5. Global Injectable Drug Delivery Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Opportunities Analysis
5.3. Product/Market Life Cycle Analysis

6. Global Injectable Drug Delivery Market – By Type
6.1. Pharmaceutical Drug Formulations
6.2. By Device
6.2.1. Conventional Devices
6.2.2. Auto Injector Devices
6.2.3. Self Injector Devices
6.2.4. Pen Injectors
6.2.5. Needle Free Injector Devices
6.3. Others

7. Global Injectable Drug Delivery Market - By Type of Diseases
7.1. Anemia
7.2. Diabetes
7.3. Multiple sclerosis
7.4. Rheumatoid
7.5. Crohn's
7.6. Others

8. Global Injectable Drug Delivery Market -Geographic Analysis
8.1. Introduction
8.2. North America
8.2.1. Canada
8.2.2. Haiti
8.2.3. Mexico
8.2.4. USA
8.2.5. Others
8.3. South & Central America
8.3.1. Argentina
8.3.2. Brazil
8.3.3. Chile
8.3.4. Colombia
8.3.5. Venezuela
8.3.6. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. Italy
8.4.4. Russia
8.4.5. Spain
8.4.6. Turkey
8.4.7. U.K
8.4.8. Others
8.5. APAC
8.5.1. Bangladesh
8.5.2. China
8.5.3. India
8.5.4. Nepal
8.5.5. Srilanka
8.5.6. Singapore
8.5.7. Malaysia
8.5.8. Others
8.6. ROW

9. Market Entropy
9.1. New Product Launches
9.2. M&As, Collaborations, JVs and Partnerships

10. Company Profiles (Overview, Financials, SWOT Analysis – Top 5 Companies, Developments, Product Portfolio)
10.1. Becton Dickinson and Company (BD)
10.2. Baxter International Inc.
10.3. Consort Medical PLC
10.4. Crossject SA
10.5. Eli Lilly and Company
10.6. Elcam Medical
10.7. Novo Nordisk
10.8. Owen Mumford Ltd
10.9. Sanofi
10.10. Schott AG
10.11. Terumo Corporation
10.12. Ypsomed Holding AG
10.13. Others
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3339355
Adroll
adroll